A Study of BBI608 Administrated With Sorafenib in Adult Patients With Advanced Hepatocellular Carcinoma
Status:
Completed
Trial end date:
2017-11-01
Target enrollment:
Participant gender:
Summary
This is an open-label, multicenter, phase 1 study of BBI608 in combination with Sorafenib.
This study population is adult Japanese patients with advanced hepatocellular carcinoma in
Sorafenib combination therapy.